Safety and extrapulmonary effects of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis following lung transplantation: A systematic review and meta-analysis.
Paediatr Respir RevApr 21, 2026 (epub)
Laura Venditto, Amber Neece, Federico Forgione et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the safety and efficacy of elexacaftor-tezacaftor-ivacaftor in 195 cystic fibrosis patients post-lung transplantation. The treatment showed benefits in managing complications like poor nutritional status and diabetes, with most patients tolerating it well despite some experiencing adverse events such as transaminase elevations.
Key findings
- Elexacaftor-tezacaftor-ivacaftor improved complications associated with cystic fibrosis, including poor nutritional status and diabetes.
- Most lung transplant recipients tolerated the treatment well, with some requiring adjustments to immunosuppressive medications.
- Adverse events included transaminase elevations in some patients.
Why it matters
Understanding the safety and efficacy of elexacaftor-tezacaftor-ivacaftor in post-lung transplant cystic fibrosis patients is crucial for optimizing management strategies and improving patient outcomes in this complex population.